文献速递胸部肿瘤

新辅助卡瑞利珠单抗联合阿帕替尼治疗可切除非小细胞肺癌的II期试验:3年生存结局与动态循环肿瘤DNA分析

Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses.
PubMed 文献 · Eur J Cancer · 2025-12-24

本单臂II期研究纳入可切除IIA-IIIB期NSCLC患者,接受3周期新辅助卡瑞利珠单抗联合阿帕替尼后手术,中位随访42.6个月,3年EFS、DFS和OS分别为58.9%、61.5%和92.3%。残余活肿瘤≤20%、PET/CT代谢反应和围手术期ctDNA清除与EFS改善显著相关。

要点

  • 新辅助卡瑞利珠单抗联合阿帕替尼在可切除IIA-IIIB期NSCLC中显示持续生存获益。
  • 残余活肿瘤≤20%、PET/CT代谢反应及围手术期ctDNA清除与EFS改善相关。
  • PET/CT代谢反应和围手术期ctDNA清除可能是预测生存的潜在生物标志物。

核心结论

  • 新辅助卡瑞利珠单抗联合阿帕替尼为可切除IIA-IIIB期NSCLC患者提供潜在持续获益。
  • PET/CT代谢反应和围手术期ctDNA清除可能是预测生存的潜在生物标志物。

研究设计与样本

  • 单臂II期研究,纳入可切除IIA-IIIB期NSCLC患者(IIIB期仅限T3N2,依据AJCC第8版TNM分期)。
  • 患者接受3周期新辅助卡瑞利珠单抗(200 mg,静脉,每2周一次)联合阿帕替尼(250 mg,口服,每日一次,服5天停2天),随后手术。
  • 术后4-8周接受辅助卡瑞利珠单抗单药最多12周期或研究者选择的其他策略。

主要发现

  • 中位随访42.6个月,3年EFS为58.9%(95%CI 46.9-69.1),DFS为61.5%(95%CI 48.6-72.1),OS为92.3%(95%CI 83.6-96.5)。
  • 残余活肿瘤≤20%与EFS改善更显著相关(HR 0.30,95%CI 0.13-0.72)。
  • 新辅助治疗后PET/CT代谢反应与EFS改善显著相关(HR 0.23,95%CI 0.08-0.62)。
  • 围手术期ctDNA清除与EFS改善显著相关(HR 0.23,95%CI 0.09-0.59)。

临床怎么用

  • 对于可切除IIA-IIIB期NSCLC,可考虑新辅助卡瑞利珠单抗联合阿帕替尼后手术及辅助卡瑞利珠单抗治疗。
  • 可利用PET/CT代谢反应和围手术期ctDNA清除辅助预测生存获益。

局限性

  • 单臂II期研究设计,样本量未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant camrelizumab plus apatinib has shown a promising major pathological response (primary endpoint) and pathological complete response (a secondary endpoint) in patients with resectable stage IIA-IIIB non-small-cell lung cancer (NSCLC) in a previous single-arm phase 2 trial. Here, we present the 3-year survival outcomes and potential prognostic factors with extended follow-up. METHODS: This single-arm phase 2 study enrolled patients with resectable stage IIA-IIIB NSCLC (stage IIIB, T3N2 only, according to the eighth edition of the American Joint Commission on Cancer TNM staging classification). Patients received three cycles of neoadjuvant camrelizumab (200 mg, intravenously, q2w) and apatinib (250 mg, orally, qd, for 5 days followed by 2 days off) followed by surgery. At 4-8 weeks after surgery, patients received either adjuvant camrelizumab monotherapy for up to 12 cycles or other strategies at the investigator's discretion. RESULTS: With the median follow-up of 42.6 months, the 3-year event-free survival (EFS), disease-free survival and overall survival were 58.9 % (95 % CI 46.9-69.1), 61.5 % (95 % CI 48.6-72.1), and 92.3 % (95 % CI 83.6-96.5), respectively. Among the pathological responses, residual viable tumors of ≤ 20 % were more strongly associated with improved EFS (HR 0.30, 95 % CI 0.13-0.72). Additionally, metabolic response on PET/CT after neoadjuvant treatment and ctDNA clearance during the perioperative period were significantly associated with improved EFS (HR 0.23 [95 % CI 0.08-0.62] and HR 0.23 [95 % CI 0.09-0.59], respectively). CONCLUSIONS: Neoadjuvant camrelizumab plus apatinib provides a potential sustained benefit for patients with resectable stage IIA-IIIB NSCLC. Metabolic response on PET/CT and perioperative ctDNA clearance might be potential biomarkers for predicting survival.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Guo W, Zhao L, Chen X, et al. Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses. Eur J Cancer. 2025. PMID: 41500061. doi:10.1016/j.ejca.2025.116198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。